PANTHER: For Advanced Prostate Cancer
What is the Purpose of this Study?
If you choose to join this study, you will:
Have a screening period that includes a physical exam, collection of demographic data, imaging scans, and blood draws.
Once screening is complete, you will:
- Get the study drugs apalutamide, abiraterone acetate, and prednisone over a period of 24 months
- Be asked to return to the clinic at least every four weeks for the first three months, and every three months thereafter
- At these visits, you will get a medical exam, answer questions about any medications or side effects, have routine blood tests, and will also have imaging scans about every 3 months.
After you finish all the study visits and have finished the study treatment, you will be contacted every 6 months to see how you are doing and to see what other cancer therapies you may be on.
Have a screening period that includes a physical exam, collection of demographic data, imaging scans, and blood draws.
Once screening is complete, you will:
- Get the study drugs apalutamide, abiraterone acetate, and prednisone over a period of 24 months
- Be asked to return to the clinic at least every four weeks for the first three months, and every three months thereafter
- At these visits, you will get a medical exam, answer questions about any medications or side effects, have routine blood tests, and will also have imaging scans about every 3 months.
After you finish all the study visits and have finished the study treatment, you will be contacted every 6 months to see how you are doing and to see what other cancer therapies you may be on.
What is the Condition Being Studied?
Advanced Prostate Cancer
Who Can Participate in this Study?
Adult patients with advanced prostate cancer that has spread beyond the prostate and has gotten worse after treatment with hormones (ADT).
Age Group
Adults
Participating Institutions
What is Involved?
We are doing this study to see if taking apalutamide, abiraterone acetate, and prednisone together, works in African American and Caucasian men with metastatic castrate resistant prostate cancer.
Study Details
Full Title
Prospective study of Apalutamide and Abiraterone Acetate in Chemotherapy-Naïve men with mCRPC Stratified by Race
Principal Investigator
Contacts
Genitourinary Oncology DCI Clinical Research Team
Phone: +1 919-681-1030
Protocol Number
IRB:
PRO00075097
NCT:
NCT03098836
ClinicalTrials.gov
View on ClinicalTrials.gov